OIA
RETA

Optimum Investment Advisors’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History

Optimum Investment Advisors’s Portfolio RETA Stock Details RETA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-2
Closed -$204 – 738
2023
Q2 		$204 Hold
2
– – ﹤0.01% 695
2023
Q1 		$182 Hold
2
– – ﹤0.01% 726
2022
Q4 		$76 Hold
2
– – ﹤0.01% 755
2022
Q3 		$0 Hold
2
– – ﹤0.01% 909
2022
Q2 		$0 Hold
2
– – ﹤0.01% 908
2022
Q1 		$0 Sell
2
-616
-100% -$18.3K ﹤0.01% 913
2021
Q4 		$16K Hold
618
– – 0.01% 624
2021
Q3 		$62K Hold
618
– – 0.03% 419
2021
Q2 		$87K Sell
618
-29
-4% -$3.27K 0.03% 410
2021
Q1 		$65K Hold
647
– – 0.02% 444
2020
Q4 		$80K Sell
647
-609
-48% -$80K 0.02% 399
2020
Q3 		$122K Buy
1,256
+522
+71% +$65.2K 0.04% 303
2020
Q2 		$115K Hold
734
– – 0.04% 303
2020
Q1 		$106K Sell
734
-273
-27% -$52.7K 0.04% 294
2019
Q4 		$206K Buy
1,007
+200
+25% +$36.5K 0.06% 266
2019
Q3 		$65K Buy
807
+2
+0.2% +$170 0.02% 461
2019
Q2 		$76K Buy
+805
New +$69.5K 0.02% 429

Other funds holding RETA

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Optimum Investment Advisors's RETA Position: Q3 2023 in Review

Optimum Investment Advisors sold out of Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) in Q3 2023, closing a stake of 2 shares — an estimated $204 sold.

Optimum Investment Advisors first reported a position in RETA in Q2 2019 and held it in 17 quarters. The position peaked at $206K in Q4 2019. 2 funds tracked by Wall St. Rank hold RETA as of Q3 2023.

  • Optimum Investment Advisors reported no remaining Reata Pharmaceuticals, Inc. Class A Common Stock position as of Q3 2023 after selling out during the quarter.
  • Optimum Investment Advisors sold 2 Reata Pharmaceuticals, Inc. Class A Common Stock shares in Q3 2023, an estimated $204.
  • Optimum Investment Advisors first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q2 2019 and held it in 17 quarters.
  • Optimum Investment Advisors's Reata Pharmaceuticals, Inc. Class A Common Stock position peaked at $206K in Q4 2019.
  • 2 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q3 2023.

Based on Optimum Investment Advisors's 13F filing for Q3 2023, filed 13 Oct 2023.